Serum Neurofilament Light Chain Levels and Neuropathy Severity in Diabetic Polyneuropathy
Key facts
- Who runs it
- Kanuni Sultan Suleyman Training and Research Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 88 people enrolled
- Started
- 25 Mar 2026
- Ended
- 30 Jun 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Blood Sample Collection and Clinical Assessment
- Record updated
- 20 August 2026
Who can take part
- Age
- 30 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- For the DPN+ group:
- Presence of diabetic polyneuropathy confirmed by clinical examination, Michigan Neuropathy Screening Instrument (MNSI), and nerve conduction studies
- For the DPN- group:
- Type 2 diabetes mellitus without clinical or electrophysiological evidence of diabetic polyneuropathy
Who cannot take part
- Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, hypothyroidism, alcohol abuse, chemotherapy) Renal dysfunction (eGFR < 60 mL/min/1.73 m²) Active infection or malignancy Inflammatory or autoimmune neurological diseases Central nervous system disorders (e.g., stroke, multiple sclerosis) Lumbar radiculopathy or peripheral entrapment neuropathy Severe visual impairment or balance disorders affecting testing Pregnancy Cognitive impairment preventing completion of questionnaires Patients with isolated small fiber neuropathy without electrophysiological evidence of large fiber involvement
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Diabetic polyneuropathy (DPN) is one of the most common chronic complications of diabetes mellitus and is characterized by peripheral nerve damage caused by long-term hyperglycemia. Progressive sensory loss and impairment of proprioception may lead to balance disturbances, gait instability, and an increased risk of falls. Neurofilament Light Chain (NfL) has emerged as a potential biomarker of neuroaxonal injury in several neurological disorders.
Read full original descriptionShow less
The aim of this observational cross-sectional study is to investigate the relationship between serum Neurofilament Light Chain (NfL) levels and neuropathy severity, balance performance, and fall risk in patients with diabetic polyneuropathy. Neuropathy severity will be evaluated using the Michigan Neuropathy Screening Instrument (MNSI) and electrophysiological findings, while balance performance and fall risk will be assessed using the Berg Balance Scale and the Falls Efficacy Scale-International (FES-I).
The 2 groups in the trial
- Diabetic Polyneuropathy (DPN+)
Participants with Type 2 diabetes mellitus diagnosed with diabetic polyneuropathy based on clinical examination, the Michigan Neuropathy Screening Instrument (MNSI), and electrophysiological evaluation using nerve conduction studies.
Treatment: Blood Sample Collection and Clinical Assessment
- Diabetic Control (DPN-)
Participants with Type 2 diabetes mellitus without clinical or electrophysiological evidence of diabetic polyneuropathy who will serve as the control group.
Treatment: Blood Sample Collection and Clinical Assessment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Association Between Serum Neurofilament Light Chain (NfL) Levels and Neuropathy Severity, Balance Performance, and Fall Risk in Diabetic Polyneuropathy
- Publications
- Record updated
- 20 August 2026